Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
24.55 SEK | -0.41% | +4.25% | -12.79% |
Feb. 08 | Humana AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023 | CI |
Feb. 08 | Transcript : Humana AB, Q4 2023 Earnings Call, Feb 08, 2024 |
Strengths
- The equity is one of the most attractive in the market with regard to earnings multiple-based valuation.
- The company shows low valuation levels, with an enterprise value at 0.6 times its sales.
- The company's share price in relation to its net book value makes it look relatively cheap.
- Given the positive cash flows generated by its business, the company's valuation level is an asset.
- Sales forecast by analysts have been recently revised upwards.
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
Weaknesses
- According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
- The company's currently anticipated earnings per share (EPS) growth for the next few years is a notable weakness.
- The company sustains low margins.
- The group shows a rather high level of debt in proportion to its EBITDA.
- For the last few months, analysts have been revising downwards their earnings forecast.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Healthcare Facilities & Services
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-12.79% | 111M | B | ||
-15.64% | 1.58B | - | ||
+1.77% | 1.43B | - | C+ | |
+14.00% | 1.25B | B | ||
+16.80% | 717M | - | B | |
-2.73% | 469M | B- | ||
+7.60% | 388M | - | - | |
+196.48% | 374M | - | D+ | |
+28.28% | 82.38M | - | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock
- Equities
- Stock Humana AB - Nasdaq Stockholm
- Ratings Humana AB